SMO and cancer: Hh-ligand-independent activation of GLI1 expression via loss of PTCH or oncogenic mutations in SMO have been reported for a number of cancers and pharmacological inhibition with SMO-directed inhibitors shown to block Hh signalling and cell proliferation (Taipale et al, 2000; Chen et al, 2002).